Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults (Q40557625)

30 June 2019

title

Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults (English)

1 reference

30 June 2019

0 references

1 reference

7

1 reference

30 June 2019

Anuradha Ganesan

5

object named as

Anuradha Ganesan

1 reference

30 June 2019

Tahaniyat Lalani

4

object named as

Tahaniyat Lalani

1 reference

30 June 2019

Nancy F Crum-Cianflone

1

object named as

Nancy F Crum-Cianflone

1 reference

30 June 2019

author name string

Seunghyun Won

2

1 reference

30 June 2019

Rachel Lee

3

1 reference

30 June 2019

Timothy Burgess

6

1 reference

30 June 2019

language of work or name

English

0 references

publication date

28 August 2016

1 reference

30 June 2019

published in

Vaccine

1 reference

30 June 2019

volume

34

1 reference

30 June 2019

page(s)

5040-5046

1 reference

30 June 2019

issue

41

1 reference

30 June 2019

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2016

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Influenza-associated morbidity and mortality in young and middle-aged women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Influenza in patients with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Translating the role of vitamin D3 in infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Can we translate vitamin D immunomodulating effect on innate and adaptive immunity to vaccine response?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

How important is vitamin D in preventing infections?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Serum 25-hydroxyvitamin d level and influenza vaccine immunogenicity in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Vitamin D Levels, Natural H1N1 Infection and Response to H1N1 Vaccine among HIV-Infected Individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

High prevalence of vitamin D deficiency in HIV-infected adults: what are the future research questions?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Immunogenicity and protective efficacy of influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Vitamin D deficiency: a worldwide problem with health consequences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

7 January 2021

Vitamin D and influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Epidemic influenza and vitamin D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Modulation of the immune response to respiratory viruses by vitamin D.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Vitamin D deficiency in community-acquired pneumonia: low levels of 1,25(OH)2 D are associated with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

An update on the association of vitamin D deficiency with common infectious diseases 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

The induction of systemic and mucosal immune responses following the subcutaneous immunization of mature adult mice: characterization of the antibodies in mucosal secretions of animals immunized with antigen formulations containing a vitamin D3 adju

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Efficient tetanus toxoid immunization on vitamin D supplementation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Impact of vitamin D administration on immunogenicity of trivalent inactivated influenza vaccine in previously unvaccinated children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

HIV infection, inflammation, immunosenescence, and aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.06.019

Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27577557

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Increase in pneumonia mortality among young adults and the HIV epidemic--New York City, United States

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27577557

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2016.06.019

1 reference

30 June 2019

PMCID

6560638

1 reference

30 June 2019

PubMed ID

27577557

1 reference

30 June 2019